Loading stock data…
ImmunityBio (IBRX)
$8.77+0.06 (+0.69%)
After Hours$8.76-0.01 (-0.11%)· Last close Jun 29
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ImmunityBio, Inc. in the Healthcare sector is trading at $8.77 with a market capitalization of $7.2B. Wall Street consensus targets $13.00 (3 analysts), implying a +48.2% move over the next 12 months. The stock is currently 29% below its 52-week high of $12.43, remaining 65.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +48.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $44.21M↑ | $38.28M↑ | $32.06M↑ | $26.43M↑ | $16.52M |
| Gross Profit | $43.97M↑ | $37.90M↑ | $31.88M↑ | $26.29M↑ | $16.46M |
| Operating Income | -$69.79M↓ | -$64.68M↓ | -$55.63M↑ | -$71.28M↓ | -$64.43M |
| Net Income | -$632.78M↓ | -$61.94M↑ | -$67.25M↑ | -$92.56M↑ | -$129.65M |
Peer Comparison
JNJUNHPFE
Fundamentals
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
98.22%
Volume
Today's trading volume
15.72M
Recent News
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology
XBI, which includes both SLS and IBRX, is on track for its strongest monthly performance since December 2023.
IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes
The semi-annual reconstitution of the index, based on market capitalizations as of April 30, 2026, will take effect after the U.S. market close on Friday, June 26.
IBRX Stock Climbs After-Hours: Retail Traders Bet Russell 1000 Inclusion Could Trigger Massive Index-Fund Buying
IBRX is already part of the Russell 2000, Russell 2500, and Russell 3000, with its current market cap around $7.67 billion.
Jim Cramer Says “Let ImmunityBio Be Your Speculation” to a Caller
ImmunityBio, Inc. (NASDAQ:IBRX) was among the stocks on which Jim Cramer commented, as he emphasized that SpaceX investors are betting on Elon Musk rather than the company’s earnings. When a caller mentioned that, as per their observation, the company seems to have become a “mid-cap commercial revenue generator” from a “small-cap spec play,” Cramer remarked: […]